文献速递淋巴瘤造血干细胞移植与细胞治疗

输注的CD19-CAR-T中CD4/CD8比值是疗效与毒性的预后因素

The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
PubMed 文献 · Br J Haematol · 2023-10-03

该研究分析了31例侵袭性B细胞淋巴瘤患者输注的抗CD19 CAR-T袋残余物,中位CAR+CD4+/CD8+比值为1.44,brexu-cel低于tisa-cel和axi-cel。CAR-T后3个月有缓解者输注产物中该比值低于无缓解者(0.74 vs 2.47,p=0.011),比值高于切点1.12与3个月治疗失败风险升高相关(OR 23.3,p=0.012)。

要点

  • 31例侵袭性B细胞淋巴瘤患者输注的CAR-T产物中位CAR+CD4+/CD8+比值为1.44。
  • 3个月有缓解者输注产物CAR+CD4+/CD8+比值低于无缓解者(0.74 vs 2.47,p=0.011)。
  • CAR+CD4+/CD8+比值高于1.12与3个月治疗失败风险升高相关(OR 23.3,p=0.012)。

核心结论

  • 研究数据表明CD8+ CAR-T及CAR+CD4+/CD8+比值在预测CAR-T疗效中起关键作用。

研究设计与样本

  • 研究分析了31例侵袭性B细胞淋巴瘤患者输注的抗CD19 CAR-T袋残余物。

主要发现

  • 输注产物中位CAR+CD4+/CD8+比值为1.44,brexu-cel低于tisa-cel和axi-cel。
  • CAR+CD4+/CD8+比值受采血时乳酸脱氢酶水平影响,不受年龄、既往治疗或外周血CD4+/CD8+比值影响。
  • CAR-T后3个月有缓解者输注产物中CAR+CD4+/CD8+比值低于无缓解者(0.74 vs 2.47,p=0.011)。
  • CAR+CD4+/CD8+比值高于切点1.12与3个月治疗失败风险升高相关(OR 23.3,p=0.012),与6个月治疗失败风险升高相关(OR 10,p=0.028)。
  • CAR+CD4+/CD8+比值低于1.12%者6个月无进展生存率为76%,高于1.12%者为31%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD4+ and CD8+ chimeric antigen receptor T cells (CAR-T) play different roles in the in vivo anti-tumour response, but the role of the CD4+ /CD8+ ratio among infused CAR-T has not been clearly defined yet. We analysed leftovers from infused anti-CD19 CAR-T bags of 31 patients with aggressive B-cell lymphomas. The median ratio was 1.44, lower for brexu-cel compared to tisa-cel and axi-cel. The CAR+CD4+ /CD8+ ratio was influenced by lactate dehydrogenase levels at apheresis, not by age, previous treatments or the CD4+ /CD8+ ratio in peripheral blood. Patients with a response at 3 months after CAR-T (M3) had a lower CAR+CD4+ /CD8+ ratio in the infused products compared to non-responders (ratio 0.74 vs. 2.47, p = 0.011). A CAR+CD4+ /CD8+ ratio higher than the cut point of 1.12 was associated with an increased risk of treatment failure at M3 (OR 23.3, p = 0.012) and M6 (OR 10, p = 0.028). The median 6-month PFS was 76% for patients with a ratio lower than 1.12% vs. 31% for the others. The prognostic role of the CAR+CD4+ /CD8+ ratio was independent of the costimulatory domain (CD28 vs. 4-1BB) of the product (OR 16.41, p = 0.041). Our data indicate a crucial role for CD8+ CAR-T and the CAR+CD4+ /CD8+ ratio in predicting CAR-T efficacy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Galli E, Bellesi S, Pansini I, et al. The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br J Haematol. 2023. PMID: 37789569. doi:10.1111/bjh.19117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。